SEER Seer, Inc.
Price Chart
Executive Summary
The Radoff-JEC Group (7.7% owner) filed a definitive additional proxy statement (DFAN14A) attacking Seer's CEO and board for 97% stock decline since IPO, seeking to elect three director nominees at the July 28, 2026 annual meeting. The group previously made three acquisition proposals (latest $2.40/share + CVR, 42% premium) that were rejected. This escalation in the proxy fight increases pressure on management to consider strategic alternatives.
Actionable Insight
Monitor proxy vote outcome closely; if the Radoff-JEC Group wins at least one board seat, expect accelerated strategic review or sale process. The activist's prior acquisition proposals suggest a floor near $2.40/share. Key catalyst is the July 28 annual meeting — position for potential premium realization if activist gains traction.
Key Facts
- Radoff-JEC Group owns ~7.7% of Seer outstanding shares
- Seeking election of three independent director nominees: Howard H. Berman, Joshua S. Horowitz, Luis E. Rinaldini
- Annual meeting scheduled for July 28, 2026
- Stock down 97% since December 2020 IPO
- CEO Omid Farokhzad's prior companies include BIND Therapeutics (bankruptcy), Selecta Biosciences (-93.7%), Tarveda Therapeutics (liquidation), Senti Biosciences (-98.5%)
- Group made three non-binding acquisition proposals (latest $2.40/share + CVR) rejected by board without engagement
- Board adopted poison pill after 13D filing
Financial Impact
Potential for significant stock re-rating if activist wins board seats, with prior acquisition proposal at $2.40/share (42% premium to pre-proposal price) plus contingent value rights. Current market cap ~$95M vs $219.5M cash on balance sheet.
Risk Factors
- Management may retain control due to poison pill and entrenched board
- Low probability of activist winning all three seats given small stake (7.7%)
- Stock could decline further if activist fails and no strategic changes occur
- CEO's track record suggests continued value destruction if no change
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DFAN14A Filing (Primary) | 0000921895-26-001611 |
| Document: 0000921895-26-001611-index-headers.html | 0000921895-26-001611 |
| Document: 0000921895-26-001611-index.html | 0000921895-26-001611 |
| Document: 0000921895-26-001611.txt | 0000921895-26-001611 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 15, 2026
5d ago
|
DFAN14A
| $1.71 $1.72 | ▲ +0.58% | ▲ +1.83% | $1.74 (+1.75%) |
|
Jun 15, 2026
5d ago
|
DEFA14A
| $1.71 $1.72 | ▲ +0.58% | ▲ +1.83% | $1.74 (+1.75%) |
|
Jun 15, 2026
5d ago
|
DEFA14A
| $1.71 $1.72 | ▲ +0.58% | ▲ +1.83% | $1.74 (+1.75%) |
|
Jun 11, 2026
10d ago
|
DEFA14A
| $1.70 $1.72 | ▲ +1.18% | ▲ +0.64% | $1.74 (+2.35%) |
|
Jun 9, 2026
11d ago
|
DFAN14A
| $1.69 $1.70 | ▲ +0.59% | ▼ −1.11% | $1.74 (+2.96%) |
|
Jun 3, 2026
17d ago
|
DEFA14A
| $1.85 $1.79 | ▼ −3.24% | ▼ −0.65% | $1.74 (−5.95%) |
|
Jun 3, 2026
17d ago
|
DEFA14A
| $1.85 $1.79 | ▼ −3.24% | ▼ −0.67% | $1.74 (−5.95%) |
|
May 27, 2026
24d ago
|
DFAN14A
| $1.93 $1.87 | ▼ −3.11% | ▼ −3.35% | $1.74 (−9.84%) |
|
May 22, 2026
29d ago
|
DEFA14A
| $1.79 $1.87 | ▼ −4.47% | ▼ −3.88% | $1.74 (+2.79%) |
|
May 22, 2026
29d ago
|
DEFA14A
| $1.79 $1.87 | ▼ −4.47% | ▼ −3.88% | $1.74 (+2.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access